Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascentage and Genor to Collaborate on Immunotherapy Combination

publication date: Dec 20, 2018

Ascentage Pharma of Suzhou formed a strategic collaboration with Shanghai's Genor Biopharma that will test a combination of Ascentage's MDM2-p53 inhibitor and Genor's anti-PD-1 mAb. MDM2 inhibits the function of p53 through direct protein-protein interaction, Ascentage's specialty. The two companies will conduct preclinical and clinical studies in both solid tumors and hematologic malignancies. Earlier this year, Ascentage filed for an IPO on the Hong Kong exchange. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital